Evidence map›Paper›PMID 39748726›Full record

ArticleCancer2025

A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.

Devalingam Mahalingam, Taofeek K Owonikoko, Ebrahim Delpassand, Mary F Mulcahy, Aparna Kalyan, Susanna Ulahannan, Kin Cheung, Yasayuki Izumi, Mary Johansen, Timothy Madden and 6 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Devalingam MahalingamNorthwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-2979-9894
Taofeek K OwonikokoWinship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-7724-7728
Ebrahim DelpassandExcel Diagnostics and Nuclear Oncology Center, Houston, Texas, USA.
Mary F MulcahyNorthwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Aparna KalyanNorthwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Susanna UlahannanStephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Oklahoma City, Oklahoma, USA.
Kin CheungFUJIFILM Pharmaceuticals USA, Inc, Cambridge, Massachusetts, USA.
Yasayuki IzumiFUJIFILM Pharmaceuticals USA, Inc, Cambridge, Massachusetts, USA.
Mary JohansenFUJIFILM Pharmaceuticals USA, Inc, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0003-0118-2224
Timothy MaddenFUJIFILM Pharmaceuticals USA, Inc, Cambridge, Massachusetts, USA.
Susumu ShimoyamaFUJIFILM Pharmaceuticals USA, Inc, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0002-0584-5200
Ruth Ann SubachFUJIFILM Pharmaceuticals USA, Inc, Cambridge, Massachusetts, USA.
Takeaki SuzukiFUJIFILM Pharmaceuticals USA, Inc, Cambridge, Massachusetts, USA.
David S WagesFUJIFILM Pharmaceuticals USA, Inc, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0001-7407-6727
Catherine WheelerFUJIFILM Pharmaceuticals USA, Inc, Cambridge, Massachusetts, USA.
Debra L RichardsonStephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Oklahoma City, Oklahoma, USA.

Funding

FUJIFILM Pharmaceuticals USA Inc.
6 · The paper itself

Abstract

backgroundYttrium-90 FF-21101 (

methodsThe trial was conducted as an open-label study in patients with advanced/metastatic disease. Radiologic response and safety were evaluated in patients who received 25 mCi/m

resultsFifty-seven patients (20 with ovarian carcinoma) were enrolled and treated. Patients who had ovarian and solid tumors had received a median of five and three prior therapies, respectively. No complete or partial responses were observed, so the trial was ended. The median progression-free survival was 118 days for the ovarian cohort and 55 days for the solid-tumor cohort. The most common treatment-related adverse events were thrombocytopenia (40%) and neutropenia (54%). One patient each developed fatal veno-occlusive disease and intracranial hemorrhage. Patients with higher P-cadherin levels remained on the study longer.

conclusions

Indexed as

Ovarian NeoplasmsYttrium RadioisotopesAdultAgedAged, 80 and overCadherinsFemaleHumansMaleMiddle AgedRadiopharmaceuticalsCadherinsRadiopharmaceuticalsYttrium-90Yttrium RadioisotopesFF‐21101ovarian carcinomaP‐cadherinradioimmunotherapyradiopharmaceuticalsolid tumoryttrium‐90 (90Y)

Identifiers

PMID39748726
PMCPMC11696210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.